print

Vita

Prof. Dr. med. Johannes Mann

 

Berufliche Entwicklung

Training and professional activities

 

1968-1974

Medical School in Germany and in France

 

1974

M.D., University of Heidelberg, Germany

 

1974-1976

Intern, Univ. of Heidelberg and of Kiel

 

1976-1978

Reseach fellow, Dept. of Pharmacology, Univ. of Heidelberg (with F. Gross and D. Ganten)

 

1978-1980

Senior research fellow, Clinical Research Institute of Montréal, Univ. of Montréal & McGill, Canada (with J. Genest)

 

1980-1985

Resident and senior resident, Depts. of  Medicine and of Nephrology, Univ. of Heidelberg (with E. Ritz)

 

1985-1989

Staff member and assistant professor of Medicine, Dept. of Medicine, Univ. of Heidelberg

 

1989-1992

Professor of Medicine and of Pharmacology, Univ. of Erlangen-Nuremberg, vice-chairman, Dept. of Nephrology

 

1992- today

Director, Dept. of Nephrology, Schwabing General Hospital at Munich and KfH Kidney Center, Schwabing, Munich,  Professor of Medicine, Univers. of  Erlangen-Nürnberg

 

 

Medical degrees

Board certified specialist (Facharzt) for

Pharmacology and Toxicology (1982),

Internal Medicine (1985), Nephrology (1986),

Intensive Care (1995)

 

Main research activities

Experimental:

Angiotensin and renal damage,

Physiology of vascular angiotensin formation,

Angiotensin receptor regulation,

Role of the brain renin angiotensin system in hypertension.

Human:

Angiotensin and the progression of renal disease,

Renin system and atherosclerosis,

CV disease in renal insufficiency,

Clinical pharmacology of erythropoietins and other drugs in renal failure.

 

Clinical trial steering committees and coauthorships

AIPRI study (NEJM 1996),

HOPE study (NEJM 2000, Lancet 2000, Ann Int Med 2001), DIABHYCAR study (BMJ 2004),

4D study (NEJM 2005),

HOPE-TOO study (NEJM 2006),

ONTARGET study (NEJM 2008)

Renal-ONTARGET study (Lancet 2008) Renal-TRANSCEND study (Ann Int Med 2009)

pharmacokinetics of several ACE inhibitors in renal failure,

effects of several AT1-receptor antagonists in renal failure,

erythropoietin dosage schedules in renal failure.

 

Auszeichnungen

Awards and recognitions

Promotion (similar to D.Sc.) 1974, Univ. of Heidelberg

Habilitation (similar to Ph.D.) 1985, Univ. of Heidelberg

Paul Beiersdorf Award of the German Soc. of Internal Medicine 1988;

Prix Galien 1989;

Franz Gross Science Award, German Hypertension Soc 1999.

 

Past and present editorial boards and editorships

Kidney International; Nephrology, Dialysis and Transplantation; J Hypertension; Clinical Nephrology; Nieren- und Hochdruckkrankheiten, Herz und Gefässe.

 

Mitgliedschaften

Committees

  • Officer, German Soc. Nephrology
  • Officer, German Soc. Internal Medicine
  • Ex-Member, Guideline commission, German Hypertension Soc
  • Member, Quality Assurance, German Soc. Internal Medicine
  • Ex-Member, Task force on Clinical trials of the International Soc. of Nephrology

 

 

 

zurück zum Team


Veröffentlichungen

  • Mann JFE, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Dickstein K, Keltai M, Metsärinne K, Oto A, Teo KK, Yusuf S for the ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet  372; 547 – 553, 2008
  • Kunz R, Friedrich Ch, Wolbert M; Mann JFE. Effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Int Med 148: 30-48, 2008
  • Schiffrin EL, Lipmann ML, Mann JFE.Chronic kidney disease: effects on the cardiovascular system. Circulation   116: 85 – 97, 2007
  • Wanner Ch, V Krane, W Maerz , M Olschewski, JFE Mann, M Ruf, E Ritz. Statins in the treatment of patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353: 238 – 248, 2005
  • Mann JFE, EM Lonn, QL Yi, HC Gerstein, BJ Hoogwerf, J Pogue, J Bosch, GR Dagenais, S Yusuf. Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney International 65: 1375 – 1380, 2004
  • Pinkau T, KF Hilgers, R Veelken, JFE Mann. How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease? J Am Soc Nephrol15:517 – 523, 2004
  • Mann JFE, HC Gerstein, QL Yi, EM. Lonn, BJ Hoogwerf, A Rashkow, S Yusuf Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol  2003; 14: 641-7
  • Hilgers KF, A Hartner, M Porst, R Veelken, JFE Mann Angiotensin II type 1 receptor blockade prevents lethal malignant hypertension: relation to kidney inflammation. Circulation   104: 1436 – 1440, 2001
  • Mann JFE, HC Gerstein, J Pogue, J Bosch, S Yusuf. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Int Med 134: 629 – 636, 2001
  • Hilgers KF, A Hartner, R Veelken, JFE Mann. Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury: role of the angiotensin II type 1 receptor. Kidney Intern,  58: 2408 – 2419, 2000
  • Ritz E, JFE Mann. Renal angioplasty for lowering blood pressure. N Engl J Med, 342: 1042 – 1043, 2000

 

 

zurück zum Team


Prof. Dr. med. Johannes Mann:


"In Zusammenarbeit mit weltweiten Netzen von wissenschaftlich aktiven Nephrologen stellen wir sicher, dass Sie bei uns mit den modernsten Methoden auf dem aktuellen Stand des medizinischen Wissens behandelt werden."